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Abstract
Although probabilistic analysis has become the accepted standard for decision analytic cost-effectiveness models, deter-
ministic one-way sensitivity analysis continues to be used to meet the need of decision makers to understand the impact that 
changing the value taken by one specific parameter has on the results of the analysis. The value of a probabilistic form of 
one-way sensitivity analysis has been recognised, but the proposed methods are computationally intensive. Deterministic 
one-way sensitivity analysis provides decision makers with biased and incomplete information whereas, in contrast, proba-
bilistic one-way sensitivity analysis (POSA) can overcome these limitations, an observation supported in this study by results 
obtained when these methods were applied to a previously published cost-effectiveness analysis to produce a conditional 
incremental expected net benefit curve. The application of POSA will provide decision makers with unbiased information 
on how the expected net benefit is affected by a parameter taking on a specific value and the probability that the specific 
value will be observed.
 * Andrew Sutton 
 asutton@ihe.ca
1 Institute of Health Economics, 1200, 10405 Jasper Avenue, 
Edmonton, AB, Canada
2 School of Public Health, University of Alberta, Edmonton, 
AB, Canada
3 Department of Economics, University of Alberta, Edmonton, 
AB, Canada
4 Department of Oncology, University of Edinburgh, 
Edinburgh, UK
5 Department of Emergency Medicine, University of Alberta, 
Edmonton, AB, Canada
Key Points for Decision Makers 
Deterministic one-way sensitivity analysis has a number 
of limitations and can provide biased and incomplete 
information.
Probabilistic one-way sensitivity analysis overcomes the 
shortcomings of deterministic sensitivity analysis.
1 Introduction
During the last 2 decades, comprehensive probabilistic 
sensitivity analysis (PSA) has become the recommended 
approach to examining impact of parameter uncertainty on 
the outputs of cost-effectiveness analyses (CEAs). This said, 
one-way sensitivity analysis (OSA) continues to be recog-
nised as a popular form of uncertainty analysis for CEAs. 
Drummond et al. [1] describes the process of OSA as fol-
lows: “single values for each of the input parameters are used 
to estimate the expected cost, effect and [net benefit (NB)] 
based upon their mean values. The parameter values are var-
ied and the effect on model outputs are reported.” (p. 393). 
All of these guides note that deterministic one-way analy-
sis does not provide insight into the decision uncertainty 
that concerns decision makers. Further criticisms of OSA 
include that (a) the range of values chosen is often arbitrary; 
(b) deterministic approaches will not take account of any 
correlations and non-linearities in the model, which means 
they will produce biased estimates of the expected costs and 
outcomes; and (c) the results do not tell the decision maker 
how likely it is that a specific value or range of values will 
be observed. Critics have also observed that the conventional 
way of reporting OSA—the tornado diagram—is problem-
atic because the range covered by the bars can easily be 
misinterpreted; for example, the proportion of the bar that 
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is in the positive NB space does not indicate the probability 
that the parameter will take a value that would produce a 
positive NB. In addition, tornado diagrams frequently use 
the incremental cost-effectiveness ratio (ICER) rather than 
NB as the scale for the horizontal axis, which introduces 
further complications as ICERs are neither continuously nor 
uniquely defined.
Problems with the conventional approaches to OSA do 
not alter decision makers’ legitimate concern that changes 
in one particular parameter in the decision problem may 
impact on the expected value of a technology. As Claxton 
et al. [2] observed in 2005, “in making an assessment of the 
implications of decision uncertainty when issuing guidance, 
the Appraisal Committee will also need an understanding 
of the contribution of specific parameters (or combinations 
of parameters)”. They go on to suggest that the value of 
information can meet this need. However, the expected 
value of knowing something with certainty is not the same 
as knowing what the impact of an input parameter taking a 
specific value will be on the expected costs, outcomes and 
incremental NB, i.e. value-of-information methods do not 
meet the decision makers’ information requirements that 
OSA is designed to. Drummond et al. [1] reported that once 
a threshold value has been identified, the probability of 
that value being observed can be calculated and reported 
(p395). Awotwe et al. [3] described a probabilistic version 
of tornado diagrams, constructed using the data created by 
expected value of perfect parameter information (EVPPI) 
analysis. Subsequently, Hill et al. [4] described a proba-
bilistic approach to threshold analysis for CEA. The latter 
methods are particularly computationally intensive, and the 
approach described by Drummond and colleagues provides 
the decision maker with considerably less information.
In this paper, we describe how to implement probabilistic 
one-way sensitivity analysis (POSA) using a more efficient 
approach than the EVPPI process used by Awotwe et al. [3]. 
We then propose an alternative graphical presentation for 
the outputs of this analysis—the POSA line graph, which 
addresses some of the weaknesses of tornado diagrams and 
allows the identification of threshold values referred to by 
both Drummond et al. [1] and Hill et al. [4].
OSA examines the impact on the predicted costs and out-
comes of changing the value of a specified variable while 
holding all other variables constant at their expected value. 
The intent of undertaking OSA is to support the decision 
maker to consider the question, ‘What if the specified vari-
able took a different value from the expected value used in 
the analysis?’.
Given that we are almost never certain of the true value 
of any parameter included in an economic evaluation, this 
is a sensible question for any decision maker to consider. 
However, there are two problems with the way that OSA 
addresses the question.
First, holding the value of all other parameters constant at 
their expected values assumes that the values of all param-
eters are independent of each other. For example, if the cost 
of managing an adverse event is higher than the cost used in 
the base-case analysis, the quality-of-life impact (disutility) 
of an adverse event will be unchanged. It is credible that the 
cost is higher because the adverse events are more severe, 
and in this case their impact on health-related quality of life 
should also be greater. The assumption of independence of 
parameters lacks face validity. To the extent that parameter 
values are correlated and modelled as such, the results of 
OSA will be biased.
The second problem with OSA is that it provides no 
information on how likely it is that each parameter will take 
a specific value. Establishing whether there is a possible 
parameter value that would change the recommendation is 
useful. However, theoretically possible but highly unlikely 
values should not carry the same weight in decision mak-
ing as those that are highly likely. Probabilistic analyses use 
probability density functions (PDFs) to incorporate the like-
lihood that a parameter will take each specific value. This is 
appropriate because not all possible values are equally likely 
to be the true value. OSA of a probabilistic model throws 
away this important information that is already included in 
the model.
2  Probabilistic One‑way Sensitivity Analysis 
(POSA)
While OSA is a flawed approach to meeting the needs of 
decision makers, the importance of the motivating question 
remains. It is helpful for decision makers to have insights 
into the relationship between specific input parameters and 
the model outputs, particularly the expected costs and out-
comes. It is therefore incumbent on analysts to provide as 
complete and unbiased an answer to this question as pos-
sible. What is required is POSA.
POSA requires that (1) the correlation between the value 
taken by the parameter of interest and other parameters in 
the model is reflected in the analysis and (2) that the prob-
ability of the parameter taking a specific value (the uncer-
tainty about the true value of the parameter) is promulgated 
through the model and reflected in the outputs from the 
analysis. Both of these objectives are achieved by running a 
variation of the analyses required for the conventional (two-
step) methods for calculating the EVPPI [5]. In conventional 
EVPPI, two random samples are drawn—the inner loop and 
the outer loop.
The outer loop covers the range of values in the distri-
bution of the parameter of interest. For each value drawn 
from the parameter of interest, a full PSA is run on all other 
parameters in the model, i.e. a Monte Carlo simulation is run 
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for the same number of simulations as used for the base-case 
analysis. This is referred to as the inner loop. The results 
of this inner loop are recorded and then a second value is 
drawn from the distribution for the parameter of interest and 
the inner loop PSA is repeated. For our purposes, we do 
not need to randomly sample the values that form the outer 
loop, as is conventionally done for EVPPI. Instead, we can 
systematically select the set of values to form the outer loop 
that cover the range described by the PDF of the parameter. 
In choosing the number of values forming the outer loop, 
there is a trade-off between computational efficiency and 
precision. For example, analysts may only wish to run inner 
loops corresponding to centiles or deciles of the distribution, 
rather than randomly selecting thousands of values from the 
distribution as would be done in a conventional EVPPI anal-
ysis. For illustration, Fig. 2 shows deciles. For each value of 
the distribution, we report the conditional expected incre-
mental net monetary benefit (cINMB). cINMB is conditional 
on the parameter of interest, and expected because it is a 
mean result. This allows for determination of the probabil-
ity that the cINMB is positive, given the uncertainty in the 
parameter of interest. The number of values chosen to form 
the outer loop is a decision regarding the desired precision 
in characterising the relationship between the value of the 
specific parameter and cost effectiveness. An example of 
pseudocode for POSA for an economic evaluation of two 
interventions is included in an Appendix.
3  ‘Conditional Expected Net Benefit’ 
and POSA
For each possible value of the parameter of interest, the 
above analysis provides the expected costs and outcomes 
for each technology being compared. For the purpose of a 
POSA, we wish to provide the decision maker with insight 
into the cost effectiveness of the technology for each pos-
sible value and the probability that the parameter takes a 
value that would change the decision indicated by the central 
estimate of the reference case analysis.
The limitations with ICERs as a summary measure of a 
CEA have been well-described elsewhere [6]. One limitation 
that is particularly pertinent to the construction of tornado 
diagrams is the behaviour of ICERs when the denominator 
(incremental quality-adjusted life-years [QALYs]) moves from 
a negative to a positive value. When this occurs, the ICER flips 
from a negative to a positive value. As the incremental effect 
approaches zero, the ICER moves towards infinity. It is impos-
sible to plot these outputs of a OSA using ICERs on a tornado 
diagram. Therefore, we recommend that the results of POSAs 
are plotted in the incremental NB space.
The first step in constructing the graphical representation 
of the POSA is to rank the expected costs and outcomes by 
the sampled value from the parameter of interest, over the 
range of values considered in the outer loop. In our example, 
this is from the 1st to the 99th centile.
Step two is to use the ‘reference case’ value of lambda 
(the cost-effectiveness threshold) to calculate the cINMB for 
each value of the parameter.
Step three is to read off, from the PDF, the probability of 
observing values within each centile of the parameter’s distri-
bution. This information can be used to plot a tornado diagram 
where the bar plots the credible range for the cINMB between, 
for example, the 1st and 99th centile of the parameter distri-
bution. The probability of observing a value that produces a 
positive or negative cINMB can be captured by recording the 
proportion of the parameter distribution that lies either side 
of the parameter value at which the cINMB is equal to zero.
An alternative way of presenting the same information 
is to plot a line graph of the cINMB against the centiles of 
the parameter distribution. This approach allows the deci-
sion maker to read off the probability that the parameter 
takes a value that is associated with either a positive or nega-
tive INMB. In addition, such line graphs allow the deci-
sion maker to observe whether the relationship between the 
parameter and INMB is positive or negative.
4  Example of POSA
As an example, we undertake POSA from a previously pub-
lished CEA examining the cost effectiveness of Oncotype 
DX and Prosigna genetic testing in early-stage breast cancer 
[7]. The study compared the costs and outcomes of alterna-
tive prognostic tests used to guide chemotherapy treatment 
in the management of early breast cancer, where Oncotype 
DX and Prosigna provide a test result that informs whether 
a patient is at low, intermediate or high risk (HR) of distant 
recurrence (DR) in the future. Here, we conduct POSA for 
three variables: the probability of being offered chemother-
apy following a low-risk Oncotype test result, the probabil-
ity of being offered chemotherapy following a HR Prosigna 
test result, and the relative risk (RR) reduction in the 9-year 
probability of DR following chemotherapy.
The distributions for each parameter are described in 
Table 1.
The data required for the POSA were extracted from a 
Monte Carlo EVPPI dataset for 99 outer loops for each cen-
tile of the parameter in question and 15,000 inner loops. We 
used these data to estimate the conditional expected costs 
and outcomes for Oncotype DX and Prosigna. We assumed a 
cost-effectiveness threshold of $20,000 per QALY and used 
this to calculate the cINMB for each sampled parameter 
value. This process was repeated for all three parameters.
For each parameter, the conditional expected costs and 
outcome data for each centile were obtained. Through this 
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process, we constructed a dataset consisting of the param-
eter centile value, the probability that the value would be 
observed, and the cINMB. With these data, the analyst can 
describe the expected INMB conditional upon the parameter 
taking that value, and the probability that the parameter will 
take that value.
Figure 1 is a tornado diagram showing the impact of 
increasing and decreasing each of the three parameters by 
25% on the ICER. For the parameter describing the probabil-
ity of receiving chemotherapy following a HR Prosigna test 
result, we can see it is possible for the ICER to go negative. 
However, whether this leads to a change in the conclusion 
about which test is cost effective remains unclear. For the 
probability of receiving chemotherapy following a low-risk 
Oncotype test result and the RR reduction in the probability 
of DR following chemotherapy, their ICERs cover a rela-
tively narrow range of positive values. It should be noted 
that the tornado diagram shown in this way does not provide 
information on how likely it is that any specific value within 
that range ± 25% for each parameter will be observed.
Figure 2 is a line graph plotting the cINMB for each 
parameter against its probability distribution. For ease, we 
have only plotted the cINMB for the 1st and 99th centiles 
as well as deciles 1–9 (i.e. 0.1–0.9), but the graph could be 
constructed with centiles or even smaller probability incre-
ments. Examining Fig. 2, we can see that, when taking into 
consideration the probability that a parameter will take a 
value, the results are very different to those in Fig. 1. For 
example, in the case of the ‘probability of chemotherapy 
following a HR Prosigna test result’, the probability that 
the parameter takes a value that leads to a negative cINMB 
is < 10%. This illustrates how a tornado diagram bar graph 
cannot be treated as a reliable indicator of the probability of 
specific values being observed.
5  Discussion
Decision makers have always been interested in the impact 
of specific parameters on the expected value of new tech-
nologies [8, 9]. Historically, OSAs have been presented to 
help decision makers understand this.
However, over the last decade, deterministic CEA has been 
increasingly recognised as flawed, and a general consensus 
has emerged around the importance of probabilistic analyses 
to provide decision makers with unbiased results. Probabilistic 
Table 1  Parameter distributions
DR distant recurrence, HR high risk, LR low risk, NA not applicable, RR relative risk, SD standard deviation
Distribution Mean SD Alpha Beta
Probability of chemotherapy given LR Oncotype result Beta 0.05 0.006 4 76.4
Probability of chemotherapy given HR test Prosigna result Beta 0.95 0.003 13.1 0.7
RR reduction in the risk of DR post chemotherapy Log normal − 1.3471 (log 
costs)
0.3585 (log costs) NA NA
Fig. 1  Deterministic one-way 
sensitivity analysis—tornado 
diagram
Probabilistic One-Way Sensitivity Analysis
models have also become more prevalent, as they provide sup-
port to decision makers who wish to use more nuanced deci-
sion options such as ‘risk-based patient access schemes’, ‘only 
in research’ or ‘only with research’ [10].
These developments in the methods and process of health 
technology assessment have not reduced the importance to 
decision makers of understanding the impact of specific 
parameters on expected value. Hence, analysts have con-
tinued to provide decision makers with deterministic OSAs, 
despite the recognition of its methodologic flaws. The con-
tinued use of deterministic OSAs represents a retrograde 
step in the methodological quality of CEA provided to deci-
sion makers and has largely continued because of the lack 
of a methodologically and robust computationally efficient 
alternative.
The importance of individual parameters in stochas-
tic CEA has conventionally been characterised using the 
EVPPI. However, EVPPI addresses the question, ‘What 
would be the value of eliminating uncertainty about the 
true value of the parameter?’ This is a different question 
from, ‘What is the probability that this parameter would take 
a value that changes the decision?’ As we have described, 
there is a substantial overlap in the analysis required to 
answer these questions. The primary difference is in the 
computational burden. POSA requires a much more limited 
set of outer loops compared with the thousands typically 
required for EVPPI. In addition, for POSA, the expected 
costs and outcomes for each outer loop set of simulations 
are captured, along with the sampled value of the parameter 
(e.g. centile), and these are linked to the probability that the 
parameter takes that value (which can be read off the PDF 
for the parameter used in the probabilistic analysis).
The correct estimate of the credible range for the cINMB 
and the probability that the parameter will take a value 
that will change the decision can both be presented to the 
decision makers using a line diagram that plots the cumula-
tive probability of the parameter against cINMB.
In the same way that probabilistic analyses were initially 
resisted on the grounds of excessive computational burden 
[11], it is likely that some will resist moves to replace the 
biased deterministic OSA because of the need to undertake 
two-level simulations to produce the data required for POSA. 
However, we argue that the number of additional simulations 
is trivial given the computational power of modern computers. 
Further, advances in the efficiency of the software available 
for constructing decision analytic cost-effectiveness models 
mean that such criticisms are not supported by the evidence. 
A recently completed benchmark comparison of decision ana-
lytic modelling software found that R and MATLAB could 
run value-of-information analyses for a typical model (with 
10,000 simulations) in < 1 min using a standard desktop com-
puter [12]. The use of appropriate software means that the 
production of POSA can be accomplished in similar time peri-
ods to those required for probabilistic analyses when it was 
initially advocated at the start of this century by organisations 
such as the UK National Institute of Clinical Excellence [2].
As with all developments in the presentation of analytic 
results to decision makers, care will be required to ensure 
that decision makers understand the information provided 
to them. For the tornado diagram, it will be important that 
decision makers are aware that the bar only shows the cred-
ible range for the conditional incremental NB and not the 
underlying probability of observing a value that changes 
the recommendation (by flipping the expected net monetary 
benefit from positive to negative, or vice versa). This addi-
tional information can be provided through a line graph that 
plots cumulative probability against the cINMB.
In the case of reporting the results for more than two 
interventions, it is necessary to show which intervention is 
cost effective at each parameter value. In this case, the line 
Fig. 2  Line graph probabilistic 
one-way sensitivity analysis
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for each parameter in Fig. 1 would be modified to show the 
intervention with the highest net monetary benefit at each 
centile, which would be analogous to the cost-effectiveness 
frontier used to report the results from PSAs when there are 
more than two interventions.
6  Conclusion
Decision makers are interested in the impact of specific 
parameters on the expected value of new technologies. 
Probabilistic models are increasingly the norm in CEA, and 
an efficient and accessible method for POSA is required. 
POSA is a method with modest computational burden and 
provides a simple and accessible graphical presentation of 
its outputs. Application of the method will provide decision 
makers with unbiased information on how the expected NB 
is affected by a parameter taking on a specific value and the 
probability that the specific value will be observed.
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Appendix: Pseudocode for POSA 
for evaluation comparing two interventions
This program will generate the output for a stochastic OSA 
for a single parameter (here called Para1).
It assumes the existence of a stochastic cost-effectiveness 
model for two interventions with model parameters (includ-
ing Para1) described using statistical distributions.
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